Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Polymyalgia Rheumatica Market Growth in 2025?

The market size for polymyalgia rheumatica has experienced considerable growth in the past few years. It’s expected to expand from $1.28 billion in 2024 to $1.36 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.6%. Factors contributing to this historic growth trend include heightened awareness among healthcare providers, increased usage of corticosteroids, the rise of specialty clinics, the advent of biologic therapies, and an increase in healthcare budgets.

What Is the Forecast for the Polymyalgia Rheumatica Market Size Through 2029?

The market size for polymyalgia rheumatica is projected to witness significant expansion in the coming years, increasing to $1.73 billion by 2029, with a compound annual growth rate (CAGR) of 6.2%. The anticipated growth during the forecast period can be attributed to factors such as the wider acceptance of biologics, the advancement of precision medicine, expedited drug approvals, extensive reimbursements, and an increase in clinical trials. Noteworthy trends expected during this forecast period include the progression in combination therapies, the groundbreaking advancements in personalized medicine, breakthroughs in precision medicine, the incorporation of electronic health records, and significant leaps in biomarkers.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp

What are the Key Market Players in Polymyalgia Rheumatica Market and How They’re Evolving?

Major companies operating in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Mount Sinai, NYU Langone Health, Mayo Foundation for Medical Education and Research, Hartford HealthCare, Horizon Therapeutics plc, Massachusetts General Hospital, Brigham and Women’s Hospital, Stanford Health Care, University Hospitals Bristol NHS Foundation Trust, Circle Health Group Ltd., Siloam Hospital, UC San Diego Health, Vejthani Hospital, Sparrow Pharmaceuticals Inc., Johns Hopkins Arthritis Center, Upstate University Hospital

What Are the Primary Growth Drivers in the Polymyalgia Rheumatica Market?

The increasing popularity of personalized medicine is anticipated to boost the polymyalgia rheumatica market’s expansion. Personalized medicine, which is adjusted to an individual’s genetic makeup, lifestyle, and specific health conditions for more effective results, drives this demand. The rise in personalized medicine is powered by developments in genetic research, increasing patient expectations for individualized treatments, and advancements in diagnostic technologies. A wealth of insights into individual genetic variations have been provided by genetic research, ushering in a new era of treatments targeted towards specific genetic markers. Personalized medicine aids in choosing the most likely effective drugs based on a patient’s characteristics, resulting in a more effective and safer treatment strategy. As per the Personalised Medicine Coalition, for example, in February 2024, a US healthcare organization revealed, the Food and Drug Administration had approved 16 novel personalized treatments for rare diseases in 2023, a significant increase from just six in 2022. Hence, the upsurge of personalized medicine is spurring the growth of the polymyalgia rheumatica market. The surge in telemedicine services due to increased convenience and remote care is fuelling the expansion of the polymyalgia rheumatica market. Using digital communication mediums like video calls, phone calls, and online messaging, telemedicine services render remote consultations, diagnoses, treatments, and follow-up care, eliminating the need for patients to physically visit healthcare facilities. The unprecedented growth in telemedicine services is owed to the rising demand for convenient and cost-effective healthcare solutions. Telemedicine caters to the popular demand for convenience, especially for non-emergency consultations, by removing the need for physical visits. The rise in telemedicine services assists polymyalgia rheumatica (PMR) by facilitating symptoms’ remote surveillance, medication management, and regular follow-ups, all essential for managing chronic pain and inflammation. For example, in November 2024, according to the Australian Bureau of Statistics, a government agency based in Australia, telehealth consultation usage rose from 87.7% in 2022-23 to 89.2% in 2023-24. As a result, the expansion of telemedicine services is catalysing the growth of the polymyalgia rheumatica market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=22103&type=smp

What Are the Leading Segments in the Global Polymyalgia Rheumatica Industry?

The polymyalgia rheumatica market covered in this report is segmented –

1) By Treatment: Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Biologics

2) By Route Of Administration: Oral, Intravenous, Subcutaneous

3) By Patient Type: Adult, Geriatric, Periatric

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Aspirin, Celecoxib

3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine

4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-6 (IL-6) Inhibitors, B-Cell Inhibitors, Janus Kinase (JAK) Inhibitors

What Are the Key Market Trends in the Polymyalgia Rheumatica Industry?

Leading companies in the polymyalgia rheumatica market are making strides in the production of advanced medications like interleukin-6 (IL-6) receptor blockers, aimed at offering more specific and impactful treatment choices. IL-6 receptor blockers, which are bio-drugs that suppress IL-6, an important inflammatory factor in autoimmune conditions, work by inhibiting IL-6, which in turn alleviates inflammation and symptoms, thereby improving the standard of living for patients with PMR. In February 2023, Regeneron Pharmaceuticals Inc., an American biotech firm, and Sanofi, a French healthcare establishment, reported FDA approval for Kevzara (sarilumab) to treat adult PMR patients who have had inadequate reactions to corticosteroids or are unable to endure the tapering process. Kevzara, the first and sole biologic approved for this disease, operates by blocking IL-6 mediated signaling. This sanction was grounded on research that showed that 28.3% of patients treated with sarilumab attained consistent remission at the 52-week mark, in comparison to a 10.3% remission rate in placebo-administered patients. It is given via a subcutaneous injection on a bi-weekly basis and is also sanctioned for the treatment of moderately to severely active rheumatoid arthritis. Sanofi’s share value (SNY) on the NASDAQ currently stands at $54.13.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report

What Is the Regional Outlook for the Polymyalgia Rheumatica Market?

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22103

This Report Delivers Insight On:

1. How big is the polymyalgia rheumatica market, and how is it changing globally?

2. Who are the major companies in the polymyalgia rheumatica market, and how are they performing?

3. What are the key opportunities and risks in the polymyalgia rheumatica market right now?

4. Which products or customer segments are growing the most in the polymyalgia rheumatica market?

5. What factors are helping or slowing down the growth of the polymyalgia rheumatica market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model